Nikhil Lalwani, President, CEO and Director of ANI Pharmaceuticals Inc., disposed of 5,400 common shares on August 25, 2026, under a Rule 10b5-1 trading plan adopted May 26, 2026.
The transaction, valued at $401,220, was executed at prices ranging from $73.58 to $74.61 per share, with a weighted average price of $74.30. Following the sale, Lalwani retains a direct holding of 344,489 shares in the company.
ANI Pharmaceuticals’ stock was trading at $74.56 at the time of publication, near its 52-week low of $70.15. The company has a market capitalization of approximately $1.62 billion and a price-to-earnings ratio of 16.25.
The insider sale follows the company’s Q2 2026 results, which reported adjusted earnings per share of $2.21, exceeding Wall Street’s $2.03 estimate, and record revenue of $266 million, surpassing the projected $262.14 million. However, full-year guidance for Cortrophin, the company’s flagship product, was revised downward by $20 million to $25 million due to underperformance in the first half of the year.
Analysts have adjusted price targets in response. Guggenheim maintained a buy rating but lowered its target from $124 to $119. Canaccord Genuity kept its hold rating but trimmed its target from $91 to $90, citing concerns over Cortrophin’s performance as a key factor.
